UroGen Pharma Ltd. Reports Strong Second‑Quarter Results and Raises Outlook
UroGen Pharma Ltd. (Nasdaq: URGN) disclosed its second‑quarter 2026 financial results on August 5, 2026. The biopharmaceutical company, which focuses on uro‑oncology therapies, reported net product revenue of $50.4 million for its flagship intravesical solution, ZUSDURI. This represents a 73 % quarter‑over‑quarter increase and exceeds analyst expectations by $8.96 million.
Revenue and Earnings Highlights
| Item | Q2 2026 | Y/Y | Notes |
|---|---|---|---|
| Net product revenue (ZUSDURI) | $50.4 million | 73 % QoQ growth | Exceeds forecast |
| GAAP EPS | –$0.28 | In‑line with guidance | Negative earnings |
| Operating expense (OPEX) target | $260–$270 million | FY 2026 | Projected 73 % QoQ growth |
The company’s earnings call, hosted on Nasdaq’s platform, confirmed that the revenue beat was driven by increased utilization, expanding adoption across community practices, and growing repeat use of ZUSDURI. Management reiterated that a new U.S. patent, once issued, will provide intellectual‑property protection for both ZUSDURI and the investigational product UGN‑103 through July 2044.
Pipeline and Commercial Outlook
- ZUSDURI: The product continues to establish itself as a foundational therapy for adult patients with recurrent low‑grade intermediate‑risk non‑muscle‑invasive bladder cancer. In‑depth analysis of the Phase 3 ENVISION trial indicates a 36‑month duration of response (DOR) of 64.5 % (95 % CI: 54.6–72.8 %).
- UGN‑103: On‑track for New Drug Application (NDA) submission in Q3 2026. The life‑cycle expansion strategy is expected to further strengthen the franchise.
- UGN‑501: Expected to enter a Phase 1 trial in Q4 2026.
The company’s updated fiscal‑year outlook reflects a revenue target of $260–$270 million and maintains confidence in the long‑term sustainability of the franchise.
Market Reaction
Following the earnings release, URGN shares rose, reaching a 52‑week high of $43.97 on August 5, 2026. The stock’s price target was increased by Guggenheim Partners to $58 after the sales beat, reflecting an optimistic view of the company’s commercial trajectory. In a broader market context, URGN was listed among the top biotech gainers for the day, alongside Attovia Therapeutics, American Well, and Perrigo.
Summary
UroGen Pharma’s Q2 performance demonstrates significant revenue growth, a strengthening commercial position for ZUSDURI, and progress on key pipeline assets. Despite negative GAAP earnings, the company’s revised outlook and elevated analyst price target suggest market confidence in its long‑term value proposition.
